Evaluation of the cochleovestibular function in patients treated with carboplatin for ovarian carcinoma.
Carboplatin (JM8), a new cisdiamminodichloroplatin (CDDP) analogue, has exhibited the same antitumor as CDDP. In our pilot study, aiming at optimizing the dosage of this drug in a combination regimen with other chemotherapics, we planned to evaluate the existence of drug related damage on cochleo-vestibular structures. The study was performed on 9 patients suffering from advanced ovarian carcinoma. The results obtained in our study showed that patients undergoing carboplatin chemotherapy do not require an audiometric check-up. In order to assess definitely the existence of vestibular toxicity of this drug, larger studies planned to test JM8 in a high-dosage regimen are desirable.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin; D003051:Cochlea / Q000187:drug effects*; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced; D006320:Hearing Tests; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014722:Vestibule, Labyrinth / Q000187:drug effects*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin